Subject(s)
Acute Kidney Injury/epidemiology , Hypertension/epidemiology , Kidney/physiopathology , Peripheral Arterial Disease/epidemiology , Vascular Stiffness , Acute Kidney Injury/diagnosis , Acute Kidney Injury/physiopathology , Blood Pressure , Carotid-Femoral Pulse Wave Velocity , Glomerular Filtration Rate , Humans , Hypertension/diagnosis , Hypertension/physiopathology , Incidence , Peripheral Arterial Disease/diagnosis , Peripheral Arterial Disease/physiopathology , Prognosis , Randomized Controlled Trials as Topic , Risk Assessment , Risk Factors , Time FactorsABSTRACT
[Figure: see text].
Subject(s)
Aging/physiology , Endothelium, Vascular , Mitochondria , Sodium Nitrite , Aged , Animals , Biomarkers/analysis , Biomarkers/blood , Dietary Supplements , Drug Monitoring/methods , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Female , Humans , Metabolomics/methods , Mice , Mitochondria/drug effects , Mitochondria/metabolism , Models, Animal , Oxidative Stress/physiology , Sodium Nitrite/administration & dosage , Sodium Nitrite/adverse effects , Sodium Nitrite/blood , Treatment OutcomeABSTRACT
See Article Naser et al.
Subject(s)
Drinking Water , Bangladesh , Blood Pressure , Drinking , Minerals , SalinityABSTRACT
Excess reactive oxygen species production by mitochondria is a key mechanism of age-related vascular dysfunction. Our laboratory has shown that supplementation with the mitochondrial-targeted antioxidant MitoQ improves vascular endothelial function by reducing mitochondrial reactive oxygen species and ameliorates arterial stiffening in old mice, but the effects in humans are unknown. Here, we sought to translate our preclinical findings to humans and determine the safety and efficacy of MitoQ. Twenty healthy older adults (60-79 years) with impaired endothelial function (brachial artery flow-mediated dilation <6%) underwent 6 weeks of oral supplementation with MitoQ (20 mg/d) or placebo in a randomized, placebo-controlled, double-blind, crossover design study. MitoQ was well tolerated, and plasma MitoQ was higher after the treatment versus placebo period (P<0.05). Brachial artery flow-mediated dilation was 42% higher after MitoQ versus placebo (P<0.05); the improvement was associated with amelioration of mitochondrial reactive oxygen species-related suppression of endothelial function (assessed as the increase in flow-mediated dilation with acute, supratherapeutic MitoQ [160 mg] administration; n=9; P<0.05). Aortic stiffness (carotid-femoral pulse wave velocity) was lower after MitoQ versus placebo (P<0.05) in participants with elevated baseline levels (carotid-femoral pulse wave velocity >7.60 m/s; n=11). Plasma oxidized LDL (low-density lipoprotein), a marker of oxidative stress, also was lower after MitoQ versus placebo (P<0.05). Participant characteristics, endothelium-independent dilation (sublingual nitroglycerin), and circulating markers of inflammation were not different (all P>0.1). These findings in humans extend earlier preclinical observations and suggest that MitoQ and other therapeutic strategies targeting mitochondrial reactive oxygen species may hold promise for treating age-related vascular dysfunction. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02597023.
Subject(s)
Antioxidants/administration & dosage , Brachial Artery/physiology , Endothelium, Vascular/metabolism , Mitochondria/metabolism , Oxidative Stress/drug effects , Vascular Stiffness/drug effects , Vasodilation/drug effects , Aged , Cross-Over Studies , Dietary Supplements , Double-Blind Method , Endothelium, Vascular/drug effects , Female , Follow-Up Studies , Healthy Volunteers , Humans , Male , Middle Aged , Reactive Oxygen Species/metabolismABSTRACT
We hypothesized that curcumin would improve resistance and conduit artery endothelial function and large elastic artery stiffness in healthy middle-aged and older adults. Thirty-nine healthy men and postmenopausal women (45-74 yrs) were randomized to 12 weeks of curcumin (2000 mg/day Longvida®; n=20) or placebo (n=19) supplementation. Forearm blood flow response to acetylcholine infusions (FBFACh; resistance artery endothelial function) increased 37% following curcumin supplementation (107±13 vs. 84±11 AUC at baseline, P=0.03), but not placebo (P=0.2). Curcumin treatment augmented the acute reduction in FBFACh induced by the nitric oxide synthase inhibitor NG monomethyl-L-arginine (L-NMMA; P=0.03), and reduced the acute increase in FBFACh to the antioxidant vitamin C (P=0.02), whereas placebo had no effect (both P>0.6). Similarly, brachial artery flow-mediated dilation (conduit artery endothelial function) increased 36% in the curcumin group (5.7±0.4 vs. 4.4±0.4% at baseline, P=0.001), with no change in placebo (P=0.1). Neither curcumin nor placebo influenced large elastic artery stiffness (aortic pulse wave velocity or carotid artery compliance) or circulating biomarkers of oxidative stress and inflammation (all P>0.1). In healthy middle-aged and older adults, 12 weeks of curcumin supplementation improves resistance artery endothelial function by increasing vascular nitric oxide bioavailability and reducing oxidative stress, while also improving conduit artery endothelial function.
Subject(s)
Curcumin/pharmacology , Endothelium, Vascular/drug effects , Oxidative Stress/drug effects , Regional Blood Flow/drug effects , Acetylcholine/pharmacology , Aged , Brachial Artery/drug effects , Female , Forearm/blood supply , Humans , Male , Middle Aged , Nitric Oxide/metabolism , Vasodilator Agents/pharmacologyABSTRACT
We hypothesized that supplementation with trehalose, a disaccharide that reverses arterial aging in mice, would improve vascular function in middle-aged and older (MA/O) men and women. Thirty-two healthy adults aged 50-77 years consumed 100 g/day of trehalose (n=15) or maltose (n=17, isocaloric control) for 12 weeks (randomized, double-blind). In subjects with Δbody mass less than 2.3kg (5 lb.), resistance artery endothelial function, assessed by forearm blood flow to brachial artery infusion of acetylcholine (FBFACh), increased ~30% with trehalose (13.3±1.0 vs. 10.5±1.1 AUC, P=0.02), but not maltose (P=0.40). This improvement in FBFACh was abolished when endothelial nitric oxide (NO) production was inhibited. Endothelium-independent dilation, assessed by FBF to sodium nitroprusside (FBFSNP), also increased ~30% with trehalose (155±13 vs. 116±12 AUC, P=0.03) but not maltose (P=0.92). Changes in FBFACh and FBFSNP with trehalose were not significant when subjects with Δbody mass ≥ 2.3kg were included. Trehalose supplementation had no effect on conduit artery endothelial function, large elastic artery stiffness or circulating markers of oxidative stress or inflammation (all P>0.1) independent of changes in body weight. Our findings demonstrate that oral trehalose improves resistance artery (microvascular) function, a major risk factor for cardiovascular diseases, in MA/O adults, possibly through increasing NO bioavailability and smooth muscle sensitivity to NO.